<DOC>
	<DOCNO>NCT02254967</DOCNO>
	<brief_summary>The main objective study evaluate whether extend duration fidaxomicin therapy superior standard vancomycin therapy sustain clinical cure CDI 30 day end treatment ( Day 40 Day 55 ) .</brief_summary>
	<brief_title>A Phase IIIB/IV Study Compare Efficacy Vancomycin Therapy Extended Duration Fidaxomicin Therapy Clinical Cure Clostridium Difficile Infection ( CDI ) Older Population</brief_title>
	<detailed_description />
	<mesh_term>Vancomycin</mesh_term>
	<criteria>CDI confirm clinical symptom ( either &gt; 3 unformed bowel movement â‰¥200ml unformed stool ( subject rectal collection device ) ) 24 hour prior randomization CDI test confirm positive presence C. difficile toxin A B stool within 48 hr prior randomization . Subject agree participate another interventional study whilst participate study . Subject take requiring treat prohibited medication Subject receive one day dose therapy CDI within last 48 hour Subject experience 2 previous episode CDI 3 month prior study enrolment Subject unable swallow oral study medication . Subject current diagnosis toxic megacolon . Subject willing adhere provision treatment observation specify protocol . Subject randomize study previously , take investigational drug within 28 day 5 half life , whichever longer , prior enrollment , currently participate another clinical study may influence assessment efficacy and/or safety endpoint study , opinion Sponsor . Subject previously participate CDI vaccine study Subject hypersensitivity fidaxomicin , vancomycin component .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Aged</keyword>
	<keyword>Fidaxomicin</keyword>
	<keyword>Clostridium Difficile</keyword>
	<keyword>Vancomycin</keyword>
</DOC>